Early Life and Education
Lee Sang-hoon was born in South Korea in January 1963. He earned a Bachelor of Science and a Master's degree in biology from Seoul National University between 1982 and 1989. In 1994, he completed a Ph.D. in Molecular, Cellular, and Developmental Biology at Ohio State University. His academic journey also included postdoctoral fellowships at Harvard Medical School, the University of California, San Francisco, and Stanford Medical School.
Rise to Success
Lee's career began with research positions at various companies. He co-founded PharmAbcine in 2008 and later served as the head of the biotech division at Hanwha Solutions. In 2016, he founded ABL Bio. The company was listed on the KOSDAQ in 2018. His breakthrough came in 2025 after ABL Bio signed a $2.6 billion licensing and research deal with Eli Lilly for its Grabody-B blood-brain-barrier-penetrating bispecific antibody technology.
Key Business Strategies
ABL Bio focuses on developing bispecific antibodies, which target two molecules simultaneously. This approach aims to enhance treatment outcomes for diseases such as cancer and neurodegenerative conditions. The company's strategic focus on bispecific antibody technology and research has been pivotal to its growth. This focus enabled the deal with Eli Lilly, which propelled Lee into the billionaire ranks.
Philanthropy
Unfortunately, no data could be found related to Lee Sang-hoon's specific philanthropic contributions. Further search is required to discover his philanthropic activities.